Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Oct. 31, 2013
Oct. 31, 2012
Revenues:    
Clinical laboratory services $ 14,860 $ 15,177
Product revenues 7,663 8,434
Royalty and license fee income 1,611 2,019
Total revenues 24,134 25,630
Operating expenses:    
Cost of clinical laboratory services 9,709 9,710
Cost of product revenues 3,846 4,184
Research and development 817 1,011
Selling, general, and administrative 10,529 11,415
Provision for uncollectible accounts receivable 872 1,594
Legal 1,381 1,700
Total operating expenses 27,154 29,614
Operating loss (3,020) (3,984)
Other income (expense):    
Interest (62) (9)
Other 61 9
Foreign currency gain 297 229
Loss before income taxes (2,724) (3,755)
(Provision) benefit for income taxes (63) 64
Net loss $ (2,787) $ (3,691)
Net loss per common share:    
Basic and diluted (in Dollars per share) $ (0.07) $ (0.09)
Weighted average common shares outstanding:    
Basic and diluted (in Shares) 41,057 39,279